These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3309954)

  • 41. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
    Kim IY; Seong DH; Kim BC; Lee DK; Remaley AT; Leach F; Morton RA; Kim SJ
    Cancer Res; 2002 Jul; 62(13):3649-53. PubMed ID: 12097269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
    Kim J; Park H; Im JY; Choi WS; Kim HS
    Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Predictive value of the determination of receptors in carcinoma of the prostate].
    Castellanos JM; Galán A; Calvo MA; Schwartz S
    Rev Esp Oncol; 1984; 31(2):265-77. PubMed ID: 6085864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
    Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
    Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.
    Kanai M; Ishii K; Kanda H; Ogura Y; Kise H; Arima K; Sugimura Y
    Cancer Sci; 2008 Dec; 99(12):2435-43. PubMed ID: 19018772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.
    Kojima S; Mulholland DJ; Ettinger S; Fazli L; Nelson CC; Gleave ME
    Prostate; 2006 Jun; 66(9):971-86. PubMed ID: 16541420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molybdate and the measurements of androgen receptors in prostate cancer.
    Hawkins EF; Lieskovsky G; Markland FS
    J Clin Endocrinol Metab; 1981 Aug; 53(2):456-8. PubMed ID: 7251822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
    Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
    Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ras signaling in prostate cancer progression.
    Weber MJ; Gioeli D
    J Cell Biochem; 2004 Jan; 91(1):13-25. PubMed ID: 14689577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inability of cytoplasmic or nuclear androgen receptor content or distribution to distinguish benign from carcinomatous human prostate.
    Shain SA; Gorelic LS; Klipper RW; Ramzy I; Novicki DE; Radwin HM; Lamm DL
    Cancer Res; 1983 Aug; 43(8):3691-5. PubMed ID: 6861139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of natural and synthetic ligands for determining androgen receptors in prostatic tumors and prostatic nodular hyperplasia].
    Kushlinskiĭ NR; Bassalyk LS; Degtiar' VG
    Med Radiol (Mosk); 1983 Aug; 28(8):13-6. PubMed ID: 6193390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Androgen receptor].
    Komiya A; Ito H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():476-80. PubMed ID: 16149555
    [No Abstract]   [Full Text] [Related]  

  • 55. Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation.
    Emtage LA; Dunn PJ; Rowse AD
    Br J Urol; 1989 Jun; 63(6):627-33. PubMed ID: 2473822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranuclear distribution of androgen receptors in human prostate carcinoma.
    Kyprianou N; Gingell JC; Davies P
    J Endocrinol; 1987 Jan; 112(1):161-9. PubMed ID: 2434593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Detection of androgen receptor in human prostatic carcinomas by the autoradiography].
    Demura T; Sakashita S; Koyanagi T
    Nihon Hinyokika Gakkai Zasshi; 1984 Sep; 75(9):1423-9. PubMed ID: 6521132
    [No Abstract]   [Full Text] [Related]  

  • 58. [Sex steroid hormone receptors in cancer of the pancreas].
    Bassalyk LS; Klimenkov AA; Samoĭlenko VM; Lisianskiĭ VI; Kushlinskiĭ NE
    Vopr Onkol; 1990; 36(4):424-6. PubMed ID: 2345989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prostate cancer and androgen].
    Komiya A; Ito H
    Nihon Rinsho; 2000 Jul; 58 Suppl():35-40. PubMed ID: 11022681
    [No Abstract]   [Full Text] [Related]  

  • 60. [Technical problems in the demonstration of prostatic hormones].
    Ranft R
    Z Urol Nephrol; 1978 Oct; 71(10):689-92. PubMed ID: 735465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.